Effectiveness of Adjunctive Therapy of Emdogain®FL in Non-surgical Periodontal Treatment
NCT ID: NCT06070181
Last Updated: 2024-10-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
150 participants
INTERVENTIONAL
2024-03-01
2026-08-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main questions it aims to answer are:
* Will adjunctive treatment with Emdogain® result in a greater reduction in Bleeding on Probing and probing pocket depth compared to non-surgical periodontal treatment alone? • Will adjunctive treatment with Emdogain® lead to a greater mean Radiographic attachment level (rAL) gain per quadrant compared to non-surgical periodontal treatment alone?
* Will adjunctive treatment with Emdogain® result in a lower proportion of treated teeth requiring surgery (PPD ≥6mm) at 12 months after treatment?
Participants in the study will undergo the following tasks:
* Screening and randomization
* Receival of non-surgical periodontal treatment in all quadrants and in two quadrants adjunctive Emdogain®
* 6-month follow-up assessment
* 12-month follow-up assessment
Clinical and radiological assesment will be performed in two quadrants treated with adjunctive Emdogain® therapy and two quadrants treated with non-surgical periodontal treatment alone. This comparison will help determine the effects of adjunctive therapy with Emdogain®.
The study aims to provide insights into the safety and efficacy of adjunctive Emdogain® therapy in non-surgical periodontal treatment, specifically in patients with stage 3 and 4 periodontitis.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Emdogain Minimally Invasive Surgical Technique
NCT02551770
Flapless Emdogain in the Treatment of Periodontal Residual Pockets
NCT05823389
Enamel Matrix Derivative in Non-surgical Periodontal Treatment
NCT04449393
Does the Non-surgical Application of Enamel Matrix Derivative Reduce the Need of Periodontal Surgical Intervention in Subjects With Severe (Stage III) Periodontitis?
NCT05418621
Intervention Study of Two Protocols for Non-surgical Treatment of Chronic Periodontitis
NCT02168621
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Phase 2: Treatment After providing informed consent, screening completion and after examination by a periodontist, study treatment will be performed only once the Plaque Index (PI) of each screened patient will be \<20%. This means that randomization and the scaling phase (study treatment) will be only initiated when each individual patient was compliant with the oral hygiene instructions and the PI (as measured with Staining rondells red Directa, 4 surface plaque index, 1 rinsing 10 sec with 50 ml of water) was recorded to be \<20%.
Randomization to test or control-quadrants will be performed using statistical software after full mouth scaling and root planing has taken place. Out of the four quadrants / patient, two quadrants will be randomised to be treated according to standard care with adjunctive Emdogain® FL. The remaining two quadrants will be treated as controls (standard care; no adjunctive Emdogain® FL).
Following randomization, root planing and scaling will be performed by a calibrated dental hygienist in all quadrants under local anaesthesia (with xylocaine adrenaline 2%). First, an ultrasonic scaler (EMS) will be used and then manual scaling with LM-curettes will be performed. The hygienist will scale each root surface until the root surface is judged to be free of tartar. As part of standard care, this decision is made by the calibrated dental hygienist based on tactile experience.
Pockets of 5mm to 9mm (PPD) will be treated in the study (both Test and Control treatment). Test treatment: Emdogain® FL will be added to standard treatment i. e. Test quadrants. PrefGel® will be applied on the root surface for 2 minutes, then rinsed away with sterile saline solution for 30 seconds. The surface will be lightly dried using gauze and airblow and then Emdogain® will be applied. The Emdogain® FL application will be performed by the dental hygienist under the supervision of a periodontist. Control treatment: pockets of 5mm to 9mm (PPD) will receive standard treatment (no addition of Emdogain® FL) i. e. Control quadrants.
Additional teeth with PPD outside the range of 5mm to 9mm (PPD) may be present both in Test and/or Control quadrants. Such teeth will be treated using standard care (no Emdogain®) but they will not be included in study evaluations.
The patient will then be asked to rinse daily with an antiseptic mouth rinse twice a day (FLUX-CHX chlorhexidine 0.12% solution) until 14 days following the treatment. Antibiotics (e.g. penicillin V) may also be used in the presence of suppuration. The patient will be instructed not to brush in the treated area for 7 days following the treatment. Then only gentle brushing on buccal and lingual tooth surfaces using the roll stroke method will be recommended. The patients will be instructed not to perform any sulcular or interdental brushing before 2 weeks following the treatment.
Followed by individually planed healing controls and oral hygiene controls. (the number of visits/follow-ups will be recorded and presented.
Phase 3: 6 months follow up Examination will be carried out by a periodontist (blinded) at the six months follow up visit. Examination consists of periodontal assessments i. e. PI, BoP and PPD.
Phase 4: 12 months follow up Examination will be carried out by a periodontist (blinded) at the 12 months follow up visit. Examination consists of periodontal assessments (PI, BoP, PPD) and X-rays.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control- no adjunctive treatment
One arm is the control: two quadrants per each patient treated with non-surgical periodontal treatment alone. NO adjunctive treatment with emdogain. The two quadrants are randomized.
Non-surgical periodontal treatment
No additional/adjunctive treatment with Emdogain
Test-adjunctive treatment with Emdogain
The experimental arm is the two quadrants per patient assigned to be treated vid adjunctive Emdogain.
Enamel matrix derivate
'Applying Enamel matrix derivate in the periodontal pockets after completing the non-surgical periodontal treatment
Non-surgical periodontal treatment
No additional/adjunctive treatment with Emdogain
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Enamel matrix derivate
'Applying Enamel matrix derivate in the periodontal pockets after completing the non-surgical periodontal treatment
Non-surgical periodontal treatment
No additional/adjunctive treatment with Emdogain
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Over 18 years old
* Stage 3 or 4 periodontitis
* Residual pockets with probing depths from 5mm to 9mm with no furcation involvement and adequate plaque control
Exclusion Criteria
* Subgingival scaling and root planning performed in last 12 months
* Patients for which the use of Emdogain® is contraindicated i. e. patients with uncontrolled diabetes or other uncontrolled systemic diseases, disorders or treatments that compromise wound healing, chronic high dose steroid therapy, bone metabolic diseases, radiation or other immuno-suppressive therapy and infections or vascular impairment at the surgical site.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Region Jönköping County
OTHER_GOV
Ostergotland County Council, Sweden
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Shariel Sayardoust
Associate professor and Senior Consultant in Periodontology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shariel Sayardoust, PhD, DDS
Role: PRINCIPAL_INVESTIGATOR
Ostergotland County Council, Sweden
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre for Oral Rhabilitation
Linköping, Region Östergötland, Sweden
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Carin Starkhammar Johansson, PhD, DDS
Role: CONTACT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EMDFL2023
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.